Alabama House Bill HJR281

Alabama 2026 Regular Session

• Refer: 3/31/26
• Report Pass: 4/1/26
• Refer: 4/1/26
• Report Pass: 4/6/26
• Enrolled: 4/9/26
• Passed: 4/9/26
• Passed: 4/16/26

Caption

Urging the State Committee of Public Health to review and consider adding the novel synthetic opioid N-Propionitrile Chlorphine as a Schedule I controlled substance

Impact

If adopted, HJR281 would influence state laws concerning controlled substances, particularly by recognizing and regulating the dangers associated with emerging synthetic opioids. The inclusion of Cychlorphine as a Schedule I controlled substance would prohibit its manufacture, distribution, and possession, aligning with existing efforts to combat the opioid crisis. This legislative action may lead to enhanced preventive measures and public awareness campaigns to address the risks posed by such potent drugs, ultimately contributing to community health safety.

Summary

HJR281 is a resolution urging the State Committee of Public Health to review and consider the addition of N-Propionitrile Chlorphine, a novel synthetic opioid, to the list of Schedule I controlled substances. This resolution highlights the alarming potency of Cychlorphine, which is reported to be approximately ten times more potent than fentanyl, and underscores the growing concerns regarding its presence in the illicit drug market. The resolution aims to prompt swift action to prevent further harm caused by this substance, which poses a significant risk of overdose and death due to respiratory depression.

Sentiment

The sentiment surrounding HJR281 appears to be largely supportive, with legislators acknowledging the urgent need to address the threat posed by synthetic opioids. Public health advocates express concern over the fast-growing number of fatalities linked to these substances and emphasize the importance of proactive measures to control their availability. However, there may be concerns or contention regarding the extent of regulation and the potential ramifications for medical and pharmaceutical practices regarding pain management.

Contention

Notable points of contention surrounding HJR281 may revolve around the implications of categorizing Cychlorphine as a Schedule I drug, especially in terms of its impact on pain management therapies. Critics might argue that while the regulation is necessary, it could inadvertently hinder access to legitimate medical treatments that involve related substances. Therefore, balancing public health concerns with patient care remains a critical discussion point as the resolution progresses.